Is Vir Biotechnology, Inc. (VIR) a Buy, Sell, or Hold?
Vir Biotechnology, Inc.
NASDAQ:VIR
$9.49 USD
-$0.23 (-2.37%)
- Volume
- 1.68M
- Average Volume
- 1.89M
- Market Capitalization
- $1.6B
- P/E Ratio
- -3.03
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $11.66
- Year Low
- $4.16
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.11
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Marianne De Backer |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | VIR |
| CUSIP | 92764N102 |
| CIK | 0001706431 |
| Web | https://www.vir.bio |
| Phone | 415 906 4324 |
| Currency | USD |
| Employees | 367 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.12 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.11 |
| Quick Ratio | 7.11 |
| Cash Ratio | 3.75 |
Sales & Book Value
| Annual Sales | $68.56M |
| Price / Sales | 24.44 |
| Cash Flow | -3.02 |
| Price / Cash Flow | -3.60 |
| Price / Book | 1.72 |
Price Target and Rating
| Average Stock Price Forecast | $20.00 |
| High Stock Price Forecast | $30.00 |
| Low Stock Price Forecast | $18.00 |
| Forecast Upside/Downside | -52.55% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 12 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.16 |
| Trailing P/E Ratio | -3.03 |
| PEG Ratio | -0.10 |
| P/E Growth | -0.10 |
| Net Income | $-437.99M |
| Net Margin | -675.96% |
| Pretax Margin | -675.39% |
| Return on Equity | -53.31% |
| Return on Assets | -43.17% |
Financials Score
| AltmanZ Score | 1.92 |
| Piotroski Score | 3.00 |
| Working Capital | 449.43M |
| Total Assets | 1.03B |
| Ebit | -450.15M |
| Market Cap | 1.63B |
| Total Liabilities | 212.82M |
Poll Results
About Vir Biotechnology, Inc. (NASDAQ:VIR) Stock
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrange ... ments with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
2026-06-10 16:05:00
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. “We are pleased to welcome Tim to Vir Biotechnology's Board of Directors at a pivotal moment for the company,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “Tim brings a strong background of strategic discipline and operational insight that has he.
2026-05-18 16:05:00
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026. Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: Week 96 endpoint results from the Phas.
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
2026-05-18 10:59:55
Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified research pipeline.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
2026-05-17 15:47:57
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
2026-05-16 03:38:37
Vir Biotechnology is rated a buy, supported by a strong cash position, pivotal late-stage pipeline, and deep institutional backing. VIR's lead CHD drugs, Tobevibart and Elebsiran, target a large, underserved market with potential for high margins and accelerated regulatory approval. The Astellas partnership secures funding for oncology development, extends the cash runway into 2028, and minimizes dilution risk ahead of key catalysts.
2026-05-12 22:30:45
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
2026-05-07 06:02:48
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
2026-05-06 16:05:00
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2026. “Vir Bio delivered incredible momentum during the first quarter with positive, new VIR-5500 Phase 1 data and execution of a global agreement with Astellas in prostate cancer. The closing of our collaboration with Astellas in April has ignited the next stage of development work, bolstering our ability to move faster an.
Frequently Asked Questions
-
What is the current Vir Biotechnology, Inc. (VIR) stock price?
-
Vir Biotechnology, Inc.(NASDAQ:VIR) stock price is $9.49 in the last trading session. During the trading session, VIR stock reached the peak price of $11.66 while $4.155 was the lowest point it dropped to. The percentage change in VIR stock occurred in the recent session was --2.37% while the dollar amount for the price change in VIR stock was -$-0.23.
-
VIR's industry and sector of operation?
-
The NASDAQ listed VIR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of VIR?
-
Maninder Hora | Executive Vice President & Chief Technical Operations Officer
Brent Sabatini | Senior Vice President, Principal Accounting Officer & Chief Accounting Officer
Jason O'Byrne | Executive Vice President & Chief Financial Officer
Jennifer Eileen Towne | Executive Vice President & Chief Scientific Officer
Kiki Patel | Head of Investor Relations -
How many employees does VIR have?
-
Number of VIR employees currently stands at 367. VIR operates from 499 Illinois Street, San Francisco, CA 94158, US.
-
Link for VIR official website?
-
Official Website of VIR is: https://www.vir.bio
-
How do I contact VIR?
-
VIR could be contacted at phone #415 906 4324 and can also be accessed through its website. VIR operates from 499 Illinois Street, San Francisco, CA 94158, US.
-
How many shares of VIR are traded daily?
-
The average number of VIR shares traded daily for last 3 months was 1.89M.
-
What is the market cap of VIR currently?
-
The market value of VIR currently stands at $1.6B with its latest stock price at $9.49